Chang T M, Chirito E, Barre P, Cole C, Lister C, Resurreccion E
Artif Organs. 1979 May;3(2):127-31. doi: 10.1111/j.1525-1594.1979.tb01024.x.
ACAC hemoperfusion was used in series with a small fluid removal system for a clinical trial in the treatment of uremia. A 22-month trial included a pretest control period, test period and a post-test control period. The most significant observations from this trial are: 1) the predialysis body weight of the patient could be maintained closer to the patient's dry weight; 2) there was a significant increase in hematocrit; and 3) there was insufficient removal of urea. With the development of an effective urea removal system, a more compact artificial kidney than any presently available will become feasible.
将ACAC血液灌流与一个小型液体去除系统串联使用，用于一项治疗尿毒症的临床试验。一项为期22个月的试验包括一个预测试对照期、测试期和一个后测试对照期。该试验最显著的观察结果是：1）患者透析前体重可维持在更接近其干体重的水平；2）血细胞比容显著增加；3）尿素清除不足。随着有效尿素清除系统的发展，一种比目前任何现有产品都更紧凑的人工肾将变得可行。
